Concept Life Sciences (Concept), the integrated drug discovery, development and analytical services company, today announced it has appointed Matilda Bingham as Site Director of its Alderley Park site in Cheshire, UK, and David Higton as Principal Scientist (Biotransformation and Metabolite Identification), also based at the Alderley Park site.
Partnership drives connectivity in injectible meds
Latest NewsSwiss injection pen developer Haselmeier and Boston-based Common Sensing have partnered to develop smart connected self-injection devices that can monitor drug administration, dosing and efficacy of therapies.
Go Jelly, go
Latest NewsThe UK-based pioneer in marine biotechnologies Jellagen has closed a £3.8m funding round to boost sales of its next-generation jellyfish-based medicine. Lead investor were Newable Private Investing and the Development Bank of Wales.
Irish Iterum files for IPO on Nasdaq
Latest NewsIterum Therapeutics plans to raise up to US$92m in an initial public offering on US technology stock market Nasdaq. The Irish company develops oral and IV antibiotics for urinary tract infections and intra-abdominal infections.
Sonde Health Adds Thai Lee to Board of Directors
AppointmentsSonde Health Inc., an affiliate of PureTech Health (PureTech Health plc, PRTC.L) developing a voice-based technology platform for monitoring and diagnosing mental and physical medical conditions, today announced that Thai Lee, President and Chief Executive Officer of SHI International Corporation, has joined Sonde’s Board of Directors.
Near-term capital for Neurimmune
Latest NewsUS biotech company Biogen has exercised the option of a one-off payment to Swiss developer Neurimmune. If Biogen’s Alzheimer’s candidate Aducanumab is approved, the sales-related payments to Neurimmune will thus be reduced by 5%.
Neurimmune Appoints Fabian Buller as CBO
AppointmentsNeurimmune today announced that it has appointed Dr. Fabian Buller to the newly created position Chief Business Officer. Dr. Buller joins Neurimmune’s executive team and brings 8 years of professional experience with biotech and pharma companies.
Diabetes drug reverses PAH
Latest NewsA new study shows that a drug approved for the treatment of diabetes reverses pulmonary arterial hypertension (PAH) and prevents right heart failure in rats. Ekaterina Legchenko and colleagues say their findings could lead to new therapies for PAH and other chronic heart and lung conditions.
Targovax gives pipeline update
Latest NewsNorwegian Targovax ASA has given an update of its immunononcology and pancreatic cancer clinical pipeline at ChinaBio Conference in Suzhou.
Inhibitor-free DNA for increased reliability in PCR analysis
Sponsored PublicationsBioEcho GmbH develops kits for the isolation and processing of DNA and RNA with a rapidly expanding portfolio. With expertise and passion, we overcome the limitations of common nucleic acid extraction with pioneering methods such as the proprietary Echolution single-step technology.
Concept appoints Matilda Bingham & David Higton
AppointmentsConcept Life Sciences (Concept), the integrated drug discovery, development and analytical services company, today announced it has appointed Matilda Bingham as Site Director of its Alderley Park site in Cheshire, UK, and David Higton as Principal Scientist (Biotransformation and Metabolite Identification), also based at the Alderley Park site.